Membranous nephropathy (MN) is an autoimmune disorder characterized by the presence of specific autoantibodies. These autoantibodies are responsible for disrupting the integrity of kidney specific cells, causing MN to serve as a major cause of nephrotic syndrome in adults. While antibodies against the phospholipase A2 receptor (PLA2R) represent up to 80% cases of MN, recent studies have identified novel autoantibodies that exist in PLA2R-seronegative patients. In this webinar, Bernard Collins discusses the available tests for detection of autoantibodies in MN and describes the strategy for the discovery of novel MN antigens in renal biopsies.
Bernard Collins
Technical Director, R&D Immunopathology Unit, Massachusetts General Hospital
Associate in Pathology, Harvard Medical School
To view this webinar, please complete the following form.
2024 EUROIMMUN US
